Article
Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
Therapeutic advances in respiratory disease - 1 Jan 2000
Hu Jia, Zhang Baoshi, Yao Fangfang, Fu Yan, Chen Dianjun, Li Donghui, Du Nan, Lizaso Analyn, Song Jinlei, Zhang Lu, Li Xiaosong
Abstract excerpt
EML4-ALK rearranged malignant pleural mesothelioma (MPM) is rare and its responses to anaplastic lymphoma kinase (ALK) inhibitors, including alectinib and lorlatinib, remain unexplored. In this case report, we describe a patient with EML4-ALK-rearranged stage IIIB MPM who was administered with alectinib and lorlatinib as first-line and fourth-line therapy, respectively. He had remarkable response evaluated as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.